Renal safety of high-dose pulsed field ablation of atrial fibrillation: A prospective real-world analysis
Heart Rhythm · 2026
DOI: 10.1016/j.hrthm.2025.07.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Rhythm, 2026. Verfasst von Jake Martinez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Banner--University Medical Center in Phoenix, University of Arizona College of Medicine--Phoenix, Phoenix, Arizona. Hauptthemen laut MEDLINE: Atrial Fibrillation, Acute Kidney Injury, Catheter Ablation, Postoperative Complications. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pulsed field ablation (PFA) may lead to acute kidney injury (AKI), which is believed to be mediated by hemolysis. Although a dose-dependent response has been suspected, only a few small studies have examined the dose-range effect relationship between the number of PFA applications and renal injury. OBJECTIVE: This study aimed to assess the incidence of PFA-induced AKI in real-world practice and identify risk factors for AKI after PFA for atrial fibrillation (AF) with a high number of applications. METHODS: Data of 115 consecutive patients treated with PFA for AF were prospectively collected. Pre- and 24-hour postprocedural laboratory parameters were used to determine the development of hemolysis and AKI and were analyzed for correlation with number of PFA applications. RESULTS: Although biochemical hemolysis was ubiquitously observed after the PFA procedure, 8 patients (7%) developed AKI with only 1 case of clinically significant renal dysfunction. There was no statistical difference in PFA applications between the AKI (88.25 ± 35.37) and non-AKI groups (70.12 ± 16.94, P = .5). The change in serum creatinine (SCr) 24 hours after the procedure was comparable across 4 subgroups based on PFA applications in quartiles (P = .1). A clinically relevant increase in SCr of 0.004 mg/dL per pulse was observed only when patients received more than 38 PFA applications, leading to approximately 140 pulses being required to produce 0.3 mg/dL increase in SCr to meet the criteria of AKI. CONCLUSION: The safety margin for the number of PFA applications seems to be higher in real-world practice; delivering 70-100 PFA applications via a pentaspline catheter during AF ablation remains a relatively low risk of AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Banner--University Medical Center in Phoenix, University of Arizona College of Medicine--Phoenix, Phoenix, Arizona.
- University of Arizona College of Medicine--Phoenix, Phoenix, Arizona.
- Department of Cardiology, Banner--University Medical Center in Tucson, University of Arizona College of Medicine--Tucson, Tucson, Arizona.
- Department of Cardiology, Banner--University Medical Center in Phoenix, University of Arizona College of Medicine--Phoenix, Phoenix, Arizona. Electronic address: wilwsu@gmail.com.
Zitieren
APA
Martinez, J., Challapalli, M., Hutchinson, M., Ibrahim, M., Shen, C., Klewer, J., Fakhry, M., Weiss, J. P., Zawaneh, M., Katrapati, P., Bai, R., Tung, R., & Su, W. (2026). Renal safety of high-dose pulsed field ablation of atrial fibrillation: A prospective real-world analysis. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2025.07.026
Vancouver
Martinez J, Challapalli M, Hutchinson M, Ibrahim M, Shen C, Klewer J, et al. Renal safety of high-dose pulsed field ablation of atrial fibrillation: A prospective real-world analysis. Heart Rhythm. 2026. doi:10.1016/j.hrthm.2025.07.026
BibTeX
@article{Martinez2026,
author = {Martinez, Jake and Challapalli, Mahesh and Hutchinson, Mathew and Ibrahim, Momen and Shen, Caijie and Klewer, Jacob and Fakhry, Meer and Weiss, J Peter and Zawaneh, Michael and Katrapati, Praneeth and Bai, Rong and Tung, Roderick and Su, Wilber},
title = {Renal safety of high-dose pulsed field ablation of atrial fibrillation: A prospective real-world analysis},
journal = {Heart Rhythm},
year = {2026},
doi = {10.1016/j.hrthm.2025.07.026}
}
EUVIMED